March 27, 2019
Novartis Pharma does not want a pay-for-performance arrangement for Kymriah (tisagenlecleucel) in Japan, but is requesting the product’s pricing under the current rules, a spokesperson told Jiho on March 26 on the heels of its approval as the country’s first...read more